Artelo Biosciences presented data at the IASP 2026 World Congress on Pain showing that ART27.13, a drug in Phase 2 trials, may reduce chemotherapy-induced neuropathic pain. Nonclinical studies demonstrated ART27.13's ability to lessen pain sensitivity caused by paclitaxel, a common chemotherapy drug. The ongoing Phase 2 CAReS trial is evaluating ART27.13's effects on cancer-related symptoms including appetite loss, weight loss, and neuropathic pain. If successful, ART27.13 could become a once-daily oral treatment addressing multiple cancer symptoms, filling a significant unmet need in supportive cancer care.
Artelo Biosciences' ART27.13 drug data is highlighted here with Pluang's Health sector snapshot for context. As of Oct 29, 2026 19:12 WIB, out of 150 priced Health-sector US stocks tradable on Pluang, 91 rose and 53 fell. Notable movers include Eli Lilly And Co (LLY) at USD 1,350.62 with a 4.80% increase and 71% buy order activity, Incyte Corporation (INCY) at USD 112.32 down 3.89% but with 100% buy order activity, and Amgen, Inc. (AMGN) at USD 468.69 up 3.73% with 82% buy order activity.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
